179 related articles for article (PubMed ID: 36709793)
1. A comparative study of COVID-19 transcriptional signatures between clinical samples and preclinical cell models in the search for disease master regulators and drug repositioning candidates.
Chapola H; de Bastiani MA; Duarte MM; Freitas MB; Schuster JS; de Vargas DM; Klamt F
Virus Res; 2023 Mar; 326():199053. PubMed ID: 36709793
[TBL] [Abstract][Full Text] [Related]
2. Integrated transcriptomics reveals master regulators of lung adenocarcinoma and novel repositioning of drug candidates.
De Bastiani MA; Klamt F
Cancer Med; 2019 Nov; 8(15):6717-6729. PubMed ID: 31503425
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's disease master regulators analysis: search for potential molecular targets and drug repositioning candidates.
Vargas DM; De Bastiani MA; Zimmer ER; Klamt F
Alzheimers Res Ther; 2018 Jun; 10(1):59. PubMed ID: 29935546
[TBL] [Abstract][Full Text] [Related]
4. Integrative transcriptomics analysis of lung epithelial cells and identification of repurposable drug candidates for COVID-19.
Islam T; Rahman MR; Aydin B; Beklen H; Arga KY; Shahjaman M
Eur J Pharmacol; 2020 Nov; 887():173594. PubMed ID: 32971089
[TBL] [Abstract][Full Text] [Related]
5. Parkinson's Disease Master Regulators on Substantia Nigra and Frontal Cortex and Their Use for Drug Repositioning.
Vargas DM; De Bastiani MA; Parsons RB; Klamt F
Mol Neurobiol; 2021 Apr; 58(4):1517-1534. PubMed ID: 33211252
[TBL] [Abstract][Full Text] [Related]
6. Identifying Gene Signatures for Cancer Drug Repositioning Based on Sample Clustering.
Wang F; Ding Y; Lei X; Liao B; Wu FX
IEEE/ACM Trans Comput Biol Bioinform; 2022; 19(2):953-965. PubMed ID: 32845842
[TBL] [Abstract][Full Text] [Related]
7. Computational Drug-repositioning Approach Identifying Sirolimus as a Potential Therapeutic Option for Inflammatory Dilated Cardiomyopathy.
Shibata K; Endo T; Kuribayashi Y
Drug Res (Stuttg); 2019 Oct; 69(10):565-571. PubMed ID: 31238376
[TBL] [Abstract][Full Text] [Related]
8. Master Regulators Connectivity Map: A Transcription Factors-Centered Approach to Drug Repositioning.
De Bastiani MA; Pfaffenseller B; Klamt F
Front Pharmacol; 2018; 9():697. PubMed ID: 30034338
[TBL] [Abstract][Full Text] [Related]
9. New drug candidates for treatment of atypical meningiomas: An integrated approach using gene expression signatures for drug repurposing.
Zador Z; King AT; Geifman N
PLoS One; 2018; 13(3):e0194701. PubMed ID: 29558515
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 early infection signature identified potential key infection mechanisms and drug targets.
Li Y; Duche A; Sayer MR; Roosan D; Khalafalla FG; Ostrom RS; Totonchy J; Roosan MR
BMC Genomics; 2021 Feb; 22(1):125. PubMed ID: 33602138
[TBL] [Abstract][Full Text] [Related]
11. Transcriptomic Data Mining and Repurposing for Computational Drug Discovery.
Wang Y; Yella J; Jegga AG
Methods Mol Biol; 2019; 1903():73-95. PubMed ID: 30547437
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Signature Reversion as a Method to Reposition Drugs Against Cancer for Precision Oncology.
Koudijs KKM; Terwisscha van Scheltinga AGT; Böhringer S; Schimmel KJM; Guchelaar HJ
Cancer J; 2019; 25(2):116-120. PubMed ID: 30896533
[TBL] [Abstract][Full Text] [Related]
13. Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone.
Lawal B; Kuo YC; Rachmawati Sumitra M; Wu ATH; Huang HS
Comput Biol Med; 2022 Sep; 148():105814. PubMed ID: 35841781
[TBL] [Abstract][Full Text] [Related]
14. Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.
Hasankhani A; Bahrami A; Sheybani N; Aria B; Hemati B; Fatehi F; Ghaem Maghami Farahani H; Javanmard G; Rezaee M; Kastelic JP; Barkema HW
Front Immunol; 2021; 12():789317. PubMed ID: 34975885
[TBL] [Abstract][Full Text] [Related]
15. Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients.
Aschenbrenner AC; Mouktaroudi M; Krämer B; Oestreich M; Antonakos N; Nuesch-Germano M; Gkizeli K; Bonaguro L; Reusch N; Baßler K; Saridaki M; Knoll R; Pecht T; Kapellos TS; Doulou S; Kröger C; Herbert M; Holsten L; Horne A; Gemünd ID; Rovina N; Agrawal S; Dahm K; van Uelft M; Drews A; Lenkeit L; Bruse N; Gerretsen J; Gierlich J; Becker M; Händler K; Kraut M; Theis H; Mengiste S; De Domenico E; Schulte-Schrepping J; Seep L; Raabe J; Hoffmeister C; ToVinh M; Keitel V; Rieke G; Talevi V; Skowasch D; Aziz NA; Pickkers P; van de Veerdonk FL; Netea MG; Schultze JL; Kox M; Breteler MMB; Nattermann J; Koutsoukou A; Giamarellos-Bourboulis EJ; Ulas T;
Genome Med; 2021 Jan; 13(1):7. PubMed ID: 33441124
[TBL] [Abstract][Full Text] [Related]
16. Drug repositioning in non-small cell lung cancer (NSCLC) using gene co-expression and drug-gene interaction networks analysis.
MotieGhader H; Tabrizi-Nezhadi P; Deldar Abad Paskeh M; Baradaran B; Mokhtarzadeh A; Hashemi M; Lanjanian H; Jazayeri SM; Maleki M; Khodadadi E; Nematzadeh S; Kiani F; Maghsoudloo M; Masoudi-Nejad A
Sci Rep; 2022 Jun; 12(1):9417. PubMed ID: 35676421
[TBL] [Abstract][Full Text] [Related]
17. Drug repositioning in head and neck squamous cell carcinoma: An integrated pathway analysis based on connectivity map and differential gene expression.
Wei GG; Gao L; Tang ZY; Lin P; Liang LB; Zeng JJ; Chen G; Zhang LC
Pathol Res Pract; 2019 Jun; 215(6):152378. PubMed ID: 30871913
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
19. A Drug Repurposing Pipeline Based on Bladder Cancer Integrated Proteotranscriptomics Signatures.
Mokou M; Narayanasamy S; Stroggilos R; Balaur IA; Vlahou A; Mischak H; Frantzi M
Methods Mol Biol; 2023; 2684():59-99. PubMed ID: 37410228
[TBL] [Abstract][Full Text] [Related]
20. Inferring new drug indications using the complementarity between clinical disease signatures and drug effects.
Jang D; Lee S; Lee J; Kim K; Lee D
J Biomed Inform; 2016 Feb; 59():248-57. PubMed ID: 26707452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
